Ross Levine, M.D., is a Member of the Human Oncology and Pathogenics Program and an Attending Physician on the Leukemia Service, Department of Medicine, the Laurence Joseph Dineen Chair in Leukemia Research, a Professor of Medicine at Weill Cornell Medical College, and is the Director of the MSK Center for Hematologic Malignancies. Dr. Levine was born and raised in the New York area, and then received his AB from Harvard College and a M.D. from Johns Hopkins. Dr. Levine served as an Resident in Internal Medicine at the MGH and subsequently as a Hematology-Oncology Fellow at DFCI. His laboratory has identified MPN predisposition alleles and characterized somatic genetic alterations in MPN patients, which has improved our understanding of the genetic basis of MPNs. In addition his lab has performed preclinical studies of JAK kinase inhibitors and HSP90 inhibitors. His lab also investigates the role of somatic mutations in epigenetic modifiers in AML and mechanisms of sensitivity and resistance to epigenetic therapies. He serves on the editorial board of Blood, JCI, and on the Medical and Scientific Advisory Board of the Leukemia and Lymphoma Society. He has earned the Dameshek Prize from the American Society of Hematology, a Scholar Award from the Leukemia and Lymphoma Society, a Young Investigator Award from the American Society of Clinical Oncology, a Scholar Award from the American Society of Hematology, the Boyer Award for Clinical Investigation from MSKCC, a Clinical Scientist Development Award from the Doris Duke Charitable Foundation and a NCI Outstanding Investigator R35 award for his work on cancer epigenetics. In 2011 he was elected to the American Society of Clinical Investigation and in 2018 to the Association of American Physicians.